Associations Between Clinical Inflammatory Risk Markers, Body Composition, Heart Rate Variability, and Accelerometer-Assessed Physical Activity in University Students with Overweight and Obesity

Figures

• 

  Figure 1. Participant flow chart. BIA, bioelectrical impedance analysis; OGTT, oral glucose tolerance test; BLOOD, venous blood sampling; QUE, questionnaire; HRV, heart rate variability; ACT, accelerometry with Actigraphy wGT3X-bt.

• 

  Figure 2. Simple linear regression analyses with the respective regression lines (bold lines) and the 95% CIs (dotted lines) between clinical inflammatory markers, body composition parameters, and physical activity variables at the time of the screening visit. (a) Leucocytes and moderate physical activity (MPA); (b) Neutrophil granulocyte count and moderate physical activity (MPA); (c) Neutrophil granulocyte count and visceral adipose tissue area (VAT); (d) Immature granulocyte count and body mass index (BMI); (e) Immature granulocyte count and fat mass (FM); (f) Eosinophil granulocyte count and fat mass (FM); (g) Eosinophil granulocyte count and visceral adipose tissue area (VAT); (h) Basophilic granulocyte count and fat mass (FM); (i) Basophilic granulocyte count and visceral adipose tissue area (VAT).

• 

  Figure 3. Simple linear regression analyses with the respective regression lines (bold lines) and the 95% CIs (dotted lines) between heart rate variability parameters, inflammatory markers, and accelerometer-assessed physical activity variables during the trial period. (a) Standard deviation of normal-to-normal beat (SDNN) and moderate-to-vigorous physical activity (MVPA); (b) Root mean square of successive differences (RMSSD) and moderate-to-vigorous physical activity (MVPA); (c) High frequency (HF) and moderate-to-vigorous physical activity (MVPA); (d) High frequency (HF) and metabolic equivalent of task (MET); (e) High frequency (HF) and light-intensity physical activity (LIPA); (f) Interleukin-6 (IL-6) during the WALK condition and metabolic equivalent of task (MET); (g) Interleukin-6 (IL-6) during the WALK condition and light-intensity physical activity (LIPA); (h) Interleukin-6 (IL-6) during the SIT condition and vigorous physical activity (VPA); (i) C-reactive protein (CRP) during the STAND condition and light-intensity physical activity (LIPA).